About Us

Martyn Coombs


Martyn CoombsMr. Coombs is a recognized Industry Leader in Nuclear Medicine and Imaging. Most recently, as President of Jubilant DraxImage, he led the company through a period of rapid organic growth, tripling revenue in four years. He built a strong team, and advanced the development pipeline towards approval, specifically for Ruby-Fill®, a key PET Cardiology product. Mr. Coombs has held senior leadership roles at Amersham (now GE Healthcare), and Nihon Medi-Physics, where he was the number two Executive. Previously, he has served as CEO of Asterand PLC, a public life sciences company, where in 2008 he received an award from The Financial Times for the top performing stock on the London Stock Exchange, out of more than 2,000 companies. He has lived and worked in North America, Japan, and Europe.  Mr. Coombs holds a degree in Mathematics, and an MBA with distinction from Warwick Business School.

K. Leonard Judson


photo: K. Leonard Judson

K. Leonard Judson is the President and Managing Director of Cycad Group. Prior to co-founding Cycad Group in 2000, he practiced law for 14 years and was a partner in two law firms including May, Potenza, Judson and Baran, P.C. where he served as its CEO until his departure to the Cycad Group. Throughout his legal career a substantial portion of his practice was devoted to representing both entrepreneurs and investors in various aspects corporate law, finance, mergers and acquisitions. Leveraging upon his experience interning for the SEC and his subsequent securities law practice, Leonard was as a member of the NASD Board of Arbitrators from 1989 to 2002 and chaired numerous securities industry related arbitrations. Among his responsibilities at Cycad Group, Leonard currently serves as a Director or observer to the board of directors of several of Cycad Group’s portfolio companies including, ImaginAb, Nanosteel Corporation, Sofie Biosciences, and Lixivia. Leonard is also a Director and the Executive Vice President of the Glenn Foundation For Medical Research, Inc., a non-profit foundation supporting basic research to understand the biology of aging with the objective of developing interventions to extend the healthy years of human life. Leonard holds a J.D. with Honors, from George Washington University, Washington, D.C., and a B.S. degree, Cum Laude, from Northern Arizona University.

Thilo Schroeder, PhD


Anna M. Wu, PhDThilo Schroeder, Ph.D. is Partner at Nextech Invest Ltd., a global venture fund focused on investing in oncology companies. Prior to joining Nextech Invest in 2012, Dr. Schroeder worked in research specializing on the development of Designed Ankyrin Repeat Proteins (DARPins) as specific protein inhibitors. He acquired expertise in molecular biology as an Intern at Micromet Ltd. (now Amgen) and during his studies at the University of Sydney. Dr. Schroeder currently serves as board member of ImaginAb and board observer of Peloton Therapeutics. He is a prior board member of Blueprint Medicines (NASDAQ:BPMC), SiROP Global, and board observer of Tracon Pharmaceuticals (NASDAQ:TCON). He holds a Ph.D. in biochemistry from the University of Zurich in Switzerland, a M.Sc. in biotechnology from the Ecole de Supérieure de Biotechnologie de Strasbourg in France, and a B.Sc. in biology from the Technical University of Darmstadt in Germany.

Anna M. Wu, PhD

Founder and Chief Scientific Advisor

Anna M. Wu, PhDAnna M. Wu, Ph.D, is Professor and Chair, Department of Molecular Imaging and Therapy and Co-Director, Center for Theranostic Studies, Beckman Research of the City of Hope, and Professor in the Department of Radiation Oncology at the City of Hope National Medical Center in Duarte, CA. She also holds the title of Research Professor, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, where she previously served as Professor and Vice Chair. While at UCLA she also held positions as Director, Cancer Molecular Imaging Program, Jonsson Comprehensive Cancer Center and Co-Associate Director, Crump Institute for Molecular Imaging. She is a past Chair of the California Breast Cancer Research Council, and Fellow and Past President of the World Molecular Imaging Society. Dr. Wu received her A.B. degree in Biochemical Sciences from Harvard University, and a Ph.D. from Yale University in Molecular Biophysics and Biochemistry (MB&B). Postdoctoral studies were conducted at Yale University (MB&B) and at the University of California, San Francisco, in the Department of Biochemistry and Biophysics.


Friedhelm Blobel, PhD

Independent Non-Executive Director

Anna M. Wu, PhDFriedhelm Blobel, Ph.D., currently serves as board member of private Life Science companies (ImaginAb, ENTvantage, and SciClone Pharmaceuticals International Ltd). From June 2006 until its acquisition by a Chinese consortium in October 2017 he served as President, Chief Executive Officer and a Director for SciClone Pharmaceuticals, Inc. Throughout these years SciClone was a NASDAQ listed company, based in the San Francisco Bay Area with a specialty pharmaceuticals business focused in China, managing its own sales force and recent annual revenues of approximately $150 million. From July 2000 to 2006 Dr. Blobel was President, Chief Executive Officer and a Director of Gryphon Therapeutics, Inc., a private South San Francisco-based biopharmaceutical company. Prior to joining Gryphon Dr. Blobel spent more than two decades as an executive with the Hoechst Group and the Boehringer Mannheim Group, including responsibilities in the areas of diabetes and in vitro diagnostics. For these companies he lived and worked eight years in Europe and Japan before moving to the USA. Dr. Blobel holds a Ph.D. in Biochemistry and Microbiology from the University of Hohenheim, Germany.